https://www.selleckchem.com/pr....oducts/carfilzomib-p
New tuberculosis (T diagnostics are at a crossroads their development, evaluation, and implementation is severely damaged by resource diversion due to COVID-19. Yet several technologies, especially those with potential for non-invasive non-sputum-based testing, hold promise for efficiently triaging and rapidly confirming TB near point-of-care. Such tests are, however, progressing through the pipeline slowly and will take years to reach patients and health workers. Compellingly, such tests will create new opportunities for d
Like
Comment
Share
